371 related articles for article (PubMed ID: 33733906)
1. Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer.
Umehara K; Yama K; Goto K; Wakamoto A; Hatsuyama T; Honjo O; Saikai T; Fujita A; Sato H
Cancer Control; 2021; 28():1073274820985790. PubMed ID: 33733906
[TBL] [Abstract][Full Text] [Related]
2. Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab.
Scott SC; Pennell NA
J Thorac Oncol; 2018 Nov; 13(11):1771-1775. PubMed ID: 29935305
[TBL] [Abstract][Full Text] [Related]
3. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
4. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
Martin C; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Kowalyszyn R; Magri I; Varela M; Richardet E; Vera K; Foglia S; Jerez I; Aman E; Martinengo G; Batagelj E; Dri A; Pilnik N; Roa GM; Mando P; Tsou F; Recondo G; Cayol F; Flores M; Sena S; Bagnes C; Waisberg FD; Minatta JN; Rizzo M
Clin Lung Cancer; 2020 Sep; 21(5):e380-e387. PubMed ID: 32213298
[TBL] [Abstract][Full Text] [Related]
6. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
7. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
[TBL] [Abstract][Full Text] [Related]
8. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
Bouhlel L; Doyen J; Chamorey E; Poudenx M; Ilie M; Gal J; Guigay J; Benzaquen J; Marquette CH; Berthet JP; Mouroux J; Schiappa R; Padovani B; Hofman P; Otto J
Bull Cancer; 2020 Sep; 107(9):946-958. PubMed ID: 32646604
[TBL] [Abstract][Full Text] [Related]
9. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
[TBL] [Abstract][Full Text] [Related]
12. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
Funazo T; Nomizo T; Kim YH
J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
[No Abstract] [Full Text] [Related]
13. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
14. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
Imai H; Yamaguchi O; Mori K; Hashimoto K; Akagami T; Shinomiya S; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
Thorac Cancer; 2021 Apr; 12(8):1171-1179. PubMed ID: 33626218
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.
Enomoto T; Tamiya A; Matsumoto K; Adachi Y; Azuma K; Inagaki Y; Kouno S; Taniguchi Y; Saijo N; Okishio K; Atagi S
Clin Transl Oncol; 2021 Mar; 23(3):582-590. PubMed ID: 32661824
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
[TBL] [Abstract][Full Text] [Related]
18. Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Huang DD; Liao BC; Hsu WH; Yang CY; Lin YT; Wu SG; Tsai TH; Chen KY; Ho CC; Liao WY; Shih JY; Yu CJ; Yang JC; Cheng AL; Shen YC
Oncology; 2024; 102(4):318-326. PubMed ID: 37778345
[TBL] [Abstract][Full Text] [Related]
19. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
[TBL] [Abstract][Full Text] [Related]
20. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).
Schmid S; Diem S; Li Q; Krapf M; Flatz L; Leschka S; Desbiolles L; Klingbiel D; Jochum W; Früh M
Cancer Immunol Immunother; 2018 Dec; 67(12):1825-1832. PubMed ID: 30171269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
